Regeneron Pharmaceuticals (RGO) Stock Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. More details

RGO fundamental analysis
Snowflake Score
Valuation	6/6
Future Growth	2/6
Past Performance	1/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 72.9% below our estimate of its fair value

Earnings are forecast to grow 11.72% per year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 31.7%

Risk Analysis

RGO passed our risk checks.

RGO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Regeneron Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Regeneron Pharmaceuticals
Historical stock prices
Current Share Price	US$558.20
52 Week High	US$702.60
52 Week Low	US$464.70
Beta	0.24
1 Month Change	5.34%
3 Month Change	-12.62%
1 Year Change	n/a
3 Year Change	-15.10%
5 Year Change	13.58%
Change since IPO	5,504.42%

Recent updates

Shareholder Returns

	RGO	DE Biotechs	DE Market
7D	5.7%	0.8%	-1.7%
1Y	n/a	-7.6%	-0.6%

Return vs Industry: Insufficient data to determine how RGO performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how RGO performed against the German Market.

Price Volatility

Is RGO's price volatile compared to industry and market?
RGO volatility
RGO Average Weekly Movement	7.2%
Biotechs Industry Average Movement	8.4%
Market Average Movement	5.7%
10% most volatile stocks in DE Market	13.4%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: RGO has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: RGO's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1988	15,343	Leonard Schleifer	www.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.

Regeneron Pharmaceuticals, Inc. Fundamentals Summary

How do Regeneron Pharmaceuticals's earnings and revenue compare to its market cap?
RGO fundamental statistics
Market cap	€56.54b
Earnings (TTM)	€3.88b
Revenue (TTM)	€13.10b

14.6x

P/E Ratio

4.3x

P/S Ratio

Is RGO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGO income statement (TTM)
Revenue	US$14.92b
Cost of Revenue	US$8.37b
Gross Profit	US$6.55b
Other Expenses	US$2.12b
Earnings	US$4.42b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 30, 2026

Earnings per share (EPS)	43.48
Gross Margin	43.89%
Net Profit Margin	29.65%
Debt/Equity Ratio	6.3%

How did RGO perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/29 08:09
End of Day Share Price	2026/06/26 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regeneron Pharmaceuticals, Inc. is covered by 53 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Regeneron Pharmaceuticals (RGO) Stock Overview

Rewards

Risk Analysis

Regeneron Pharmaceuticals, Inc. Competitors

Merck KGaA

Sartorius

CSL

Vertex Pharmaceuticals

Price History & Performance

Recent News & Updates

Regeneron Pharmaceuticals, Inc. to Report Q2, 2026 Results on Jul 30, 2026

Regeneron Pharmaceuticals Regulatory Submissions for Cemdisiran Accepted for Review by FDA and EMA for Treatment of Generalized Myasthenia Gravis

Regeneron Pharmaceuticals, Inc.'s Inmazeb And Maftivimab Recommended For Investigational Use In Bundibugyo Ebolavirus Outbreak

Regeneron Pharmaceuticals, Inc. Demonstrates Lynozyfic Monotherapy Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Investor sentiment deteriorates as stock falls 17%

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Recent updates

Regeneron Pharmaceuticals, Inc. to Report Q2, 2026 Results on Jul 30, 2026

Regeneron Pharmaceuticals Regulatory Submissions for Cemdisiran Accepted for Review by FDA and EMA for Treatment of Generalized Myasthenia Gravis

Regeneron Pharmaceuticals, Inc.'s Inmazeb And Maftivimab Recommended For Investigational Use In Bundibugyo Ebolavirus Outbreak

Regeneron Pharmaceuticals, Inc. Demonstrates Lynozyfic Monotherapy Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Investor sentiment deteriorates as stock falls 17%

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals Inc Receives FDA Approval for Otarmeni Gene Therapy for Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. Demonstrates Cemdisiran Rapid, Deep And Sustained Disease Control In Generalized Myasthenia Gravis Phase 3 Trial

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Commission Approval for Dupixent to Treat Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the Extension of Dosing Intervals for Eylea Hd

Regeneron Pharmaceuticals, Inc. to Report Q1, 2026 Results on Apr 29, 2026

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Regeneron Pharmaceuticals, Inc. Announces Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

Fourth quarter dividend of US$0.94 announced

Regeneron Pharmaceuticals, Inc. Announces Upcoming Presentations from Its Ophthalmology Portfolio and Pipeline At the Virtual Angiogenesis Annual Meeting on February 7, 2026

Full year 2025 earnings released: EPS: US$43.07 (vs US$40.90 in FY 2024)

Anavex Life Sciences Corp Appoints Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology

Regeneron Pharmaceuticals, Inc. to Report Q4, 2025 Results on Jan 30, 2026

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Alvotech and Teva Pharmaceuticals Reach a Settlement and License Agreement with Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. Announces Lynozyfic Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals Announces FDA Approval Of EYLEA HD Injection 8 Mg For Treatment Of Macular Edema Following Retinal Vein Occlusion And Monthly Dosing Across Approved Indications

European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc

Regeneron Pharmaceuticals, Inc. Announces Detailed Positive Phase 2 Trial Results Evaluating Two Novel Investigational Factor Xi Antibodies - Regn7508cat and Regn9933a2

Third quarter 2025 earnings released: EPS: US$14.09 (vs US$12.40 in 3Q 2024)

Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on December 05, 2025

Regeneron Pharmaceuticals, Inc. Announces European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion for Libtayo (Cemiplimab)

Regeneron Pharmaceuticals, Inc. Announces Updated Data for Their Investigational Gene Therapy Db-Oto for Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the PD-1 Inhibitor Libtayo(Cemiplimab-Rwlc) as an Adjuvant Treatment for Adult Patients

Regeneron Pharmaceuticals, Inc. to Report Q3, 2025 Results on Oct 28, 2025

U.S. Food and Drug Administration Approves Evkeeza (Evkeeza-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi Announces That European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive CHMP Opinion

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva, Demonstrating That Garetosmab Prevents Greater Than 99% of Abnormal Bone Formation

Regeneron Pharmaceuticals, Inc. Announces Five-Year Follow-Up Results on Overall Survival from the Phase 3 Empower-Lung 3 Trial

Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023